OnKure Therapeutics’ Post

🚀 Kicking off Day 2 of the 20th BioPharma Drug Discovery Nexus Conference with a bang! Join Mauro Mileni Founder and CEO, Abilita Therapeutics, Inc. as he unveils insights into 'Enabling the Discovery of Therapeutic Antibodies Targeting Challenging Membrane Proteins'. Don't miss out on this enlightening session! #BioPharma #DrugDiscovery #Innovation #Antibodies #Therapeutics #Membraneproteins #Epitopes #Conformational #Protiens #NexusConference #SanDiego #USconference #ScientificConference

Natural Killer Cells Therapeutics Market Projected to Double to US$ 5.4 Billion by 2028 with Robust CAGR of 13.70%: DUBLIN , Jan. 3, 2024 /PRNewswire/ -- The "Global Natural Killer Cells Therapeutics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global natural killer cells therapeutics market is...

Day 1: Working on #oligonucleotide-based therapies? Connect with our WuXi TIDES team at the 9th OPT Congress in Boston from March 13-14. On March 13 at 12:45 pm EST, Yvonne Angell, Ph.D., our Executive Director and Head of TIDES discovery project management, will outline the technical challenges encountered in the discovery phase of oligonucleotide therapeutics. Through two case studies, we’ll detail our strategies for advancing programs from discovery to development, addressing technical obstacles and optimizing our approach. This presentation will offer practical insights for navigating the complexities of oligonucleotide therapy development.   Schedule a meeting with our team: WuXi_TIDES@wuxiapptec.com Learn more: https://lnkd.in/g6AmChYd #WuXiTIDES #peptides #oligonucleotides #CRDMO

Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar: The global GEP-NET therapeutics market is further expected to increase by the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, increasing research...

𝐍𝐞𝐰𝐬 𝐚𝐛𝐨𝐮𝐭 𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 Personalize medicine based on peptide has made great progress in recent years. As more and more clinical projects were initiated the demand for small scale GMP grade peptides was also picking up quickly. Hence, Intavis Peptide Services decided in 2019 to build 𝐚 𝐆𝐌𝐏 𝐀𝐏𝐈 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐲. Lo and behold, we are on schedule and eagerly await the opening ceremonies planned for Q4 of 2024. If you are you planning any 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 𝐨𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, don’t hesitate to check out 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞. #gmp #drugdevelopment #peptides #clinicaltrials #intavis

By offering these end-to-end services across the drug lifecycle, an integrated CRDMO platform,Chinese Peptide Company can provide a seamless and efficient pathway for the development, manufacturing, and commercialization of peptide and oligonucleotide therapeutics, ultimately helping clients bring their innovative treatments to market faster and more effectively. For more information, please visit：https://lnkd.in/gmNEVsqk #Peptide #oligonucleotides #manufacturing #CPC #Chinesepeptidecompany #cgmp #peptides #cdmo #api #drugdevelopment #peptidesynthesis #peptidetherapeutics #GMP

Using Native SEC-MS to quantitate aggregates Analyze monoclonal antibodies (mAbs) and mAb-derived therapeutics using Agilent native SEC/MS. Download guide: https://lnkd.in/eHYyKwxh #advancebio #mAbs

This week's top #pharma news stories...https://lnkd.in/dzZtC_35 1. Merck's #Keytruda grabs third #cervicalcancer OK, but with limited scope 2. FDA approves #Casgevy from Vertex Pharmaceuticals and CRISPR Therapeutics for beta thalassaemia 3. Daiichi Sankyo gains momentum in #ADC space, with ifinatamab deruxtecan entering late stage amidst patent battle win 4. GSK to score $1.3B in third Haleon stake sale 5. Roche’s Phase III win for #tiragolumab leaves study design questions #biopharma #biotechnology #cancer #clinicalresearch #clinicaltrials #drugdevelopment #medicalaffairs #mergersandacquisitions #pharmaceuticals #regulatoryaffairs

Catch up on a webinar, the Lumit™ FcRn Binding Immunoassay as a tool in the development of antibody-based therapeutics – Users share their experiences. Viewers will gain an understanding of Lumit™ Immunoassays, their applications, and how they simplify #FcRn binding analysis. https://bit.ly/3uTSIWK

Interested in GPCRs drug discovery? Watch this OnDemand webinar for an overview on GPCRs and novel studies implementing ꞵ-Arrestin Recruitment & GTP Gi Binding Assays for enhancing your therapeutics research.http://ms.spr.ly/60429Ji8k